INSY Insys Therapeutics Inc.

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Insys Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Insys Therapeutics, Inc. (“Insys” or the “Company”) (NASDAQ: INSY) securities between February 23, 2016 and March 15, 2017, inclusive (the “Class Period”). Insys investors have until May 16, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Insys investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to [email protected].

On March 15, 2017, Insys disclosed that it would delay the release of its financial results for the fourth quarter and full year 2016 in order to complete an independent review of the Company’s processes related to sales allowances and extended payment terms. The company further disclosed that the review could result in a reduction of 2015 net revenue and pre-tax income. On this news, shares of Insys fell approximately 5% during intraday trading on March 16, 2017, thereby injuring investors.

The Complaint filed in this class action lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Insys had overstated its 2015 net revenue; (ii) Insys had misstated its sales allowances for 2016; (iii) accordingly, the Company lacked effective internal controls over financial reporting; and (iv) as a result of the foregoing, Insys’s public statements were materially false and misleading at all relevant times.

If you purchased shares of Insys during the Class Period you may move the Court no later than May 16, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
04/04/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Insys Therapeutics Inc.

 PRESS RELEASE

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Na...

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose PHOENIX, July 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delive...

 PRESS RELEASE

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Mo...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions Operations to Continue in the Ordinary Course During Court-Supervised Process PHOENIX, June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therap...

 PRESS RELEASE

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate As...

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Continue as Normal Including Payment of Employee Wages and Benefits and Continuing Programs for Customers; Vendors and Suppliers to Receive Full Payment for Goods and Services Provided Post-Filing PHOENIX, June 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical develo...

 PRESS RELEASE

INSYS Therapeutics Reports First Quarter 2019 Results

INSYS Therapeutics Reports First Quarter 2019 Results Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update PHOENIX, May 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its first quarter ended Mar. 31, 2019. RECENT HIGHLIGHTS Appointed Andy Long as chief executive officer; in parallel promoted A...

 PRESS RELEASE

INSYS Therapeutics Implements Leadership Changes

INSYS Therapeutics Implements Leadership Changes Andrew G. Long Appointed Chief Executive Officer PHOENIX, April 15, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company. In connection with INSYS’ lead...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch